APA (7th ed.) Citation

L, C., P, O., C, F., G, M., LC, M., M, S., . . . G, B. (2026). Bevacizumab and Paclitaxel in Advanced, Hormone Receptor-Positive Breast Cancer: Multifactor Dimensionality Reduction Methodology to Identify Best Overall Survival. Oncology research, 34(5), 13. https://doi.org/10.32604/or.2026.073799

Chicago Style (17th ed.) Citation

L, Coltelli, et al. "Bevacizumab and Paclitaxel in Advanced, Hormone Receptor-Positive Breast Cancer: Multifactor Dimensionality Reduction Methodology to Identify Best Overall Survival." Oncology Research 34, no. 5 (2026): 13. https://doi.org/10.32604/or.2026.073799.

MLA (9th ed.) Citation

L, Coltelli, et al. "Bevacizumab and Paclitaxel in Advanced, Hormone Receptor-Positive Breast Cancer: Multifactor Dimensionality Reduction Methodology to Identify Best Overall Survival." Oncology Research, vol. 34, no. 5, 2026, p. 13, https://doi.org/10.32604/or.2026.073799.